1 / 17

W Hiddemann, E Hoster, C Buske, M Dreyling, M Kneba, M Hallek, E Lengfelder, H Wandt, M Unterhalt

Significant improvement of short- and long-term outcome in advanced stage follicular lymphoma: a 10-year analysis of GLSG trials. W Hiddemann, E Hoster, C Buske, M Dreyling, M Kneba, M Hallek, E Lengfelder, H Wandt, M Unterhalt. Hiddemann W, et al. Blood 2006;108:147a (Abstract 483).

alyssa-walls
Download Presentation

W Hiddemann, E Hoster, C Buske, M Dreyling, M Kneba, M Hallek, E Lengfelder, H Wandt, M Unterhalt

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Significant improvement of short- and long-term outcome in advanced stage follicular lymphoma:a 10-year analysis of GLSG trials W Hiddemann, E Hoster, C Buske, M Dreyling, M Kneba, M Hallek, E Lengfelder, H Wandt, M Unterhalt Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  2. Overall survival infollicular lymphoma 100 80 60 40 20 0 1987–1996 (n=668) 1976–1987 (n=513) 1960–1976 (n=195) Percentage 0 5 10 15 20 25 30 Horning SJ. Semin Oncol 1993;20(5 Suppl. 5):75–88

  3. Overall survival infollicular lymphoma (cont’d) 100 80 60 40 20 0 CHOP + MoAb ProMACE Percentage CHOP 0 2 4 6 8 10 Years after registration Fisher RI, et al. J Clin Oncol 2005;23:8447–52

  4. Comparison of two consecutive study generations of the GLSG R a n d o m i s a t i o n GLSG 1996 CHOP R a n d o m i s a t i o n Patients <60 years PBSCT MCP IFN-maintenance GLSG 2000 R a n d o m i s a t i o n 6–8 x CHOP + rituximab Patients ≥60 years IFN-maintenance 6–8 x CHOP Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  5. Comparison of two consecutive study generations of the GLSG Eligibility criteria • Previously untreated FL at stage III or IV and requirement for therapeutic intervention • B symptoms • bulky disease • rapid progression • haemopoietic impairment Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  6. Comparison of two consecutive study generations of the GLSG R a n d o m i s a t i o n GLSG 1996 No. of patients CHOP 381 MCP 148 GLSG 2000 R a n d o m i s a t i o n 6–8 x CHOP + rituximab 436 6–8 x CHOP 279 Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  7. Comparison of two consecutive study generations of the GLSG Risk profile according to initial therapy Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  8. Comparison of two consecutive study generations of the GLSG Risk profile over time 140 120 100 80 60 40 20 0 Parameters 1 2 3 4 5 6 7 8 9 10 Years Age Stage IV ECOG>1 LDH quotient to ULN LDH > ULN Hb g/L No. nodal areas IR FLIPI HR FLIPI Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  9. Comparison of two consecutive study generations of the GLSG Response to initial therapy Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  10. Comparison of two consecutive study generations of the GLSG Response to initial therapy Hiddemann W, et al. Blood 2006;108:147a (Abstract 483) *Adjusted for FLIPI and rituximab

  11. Comparison of two consecutive study generations of the GLSG Time to treatment failure 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 NHL 2000, median = 48 NHL 1996, median = 32 p<0.0001 Survival probability 0 12 24 36 48 60 72 84 96 108 120 Months since start of therapy Numbers of patients at risk NHL 1996 528 388 286 241 197 161 106 48 13 0NHL 2000 714 519 308 154 55 5 0 Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  12. Comparison of two consecutive study generations of the GLSG Time to treatment failure 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 MCP CHOP1 CHOP2 R-CHOP p<0.0001 Survival probability 0 12 24 36 48 60 72 84 96 108 120 Months since start of therapy Numbers of patients at risk MCP 148 112 81 69 57 49 41 23 7 0 CHOP1 308 276 205 172 140 112 65 25 6 0 CHOP2 278 210 125 60 22 2 0 R-CHOP 436 309 183 94 33 3 0 Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  13. Comparison of two consecutive study generations of the GLSG Time to treatment failure Hiddemann W, et al. Blood 2006;108:147a (Abstract 483) *Adjusted for FLIPI and rituximab

  14. Comparison of two consecutive study generations of the GLSG Overall survival 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Survival probability NHL 2000, median not reached NHL 1996, median not reached p<0.0001 0 12 24 36 48 60 72 84 96 108 120 Months since registration Numbers of patients at risk NHL 1996 538 485 457 419 386 332 242 125 46 0NHL 2000 794 621 440 250 108 8 0 Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  15. Comparison of two consecutive study generations of the GLSG (cont’d) Overall survival 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 MCP CHOP1 CHOP2 R-CHOP p<0.0001 Survival probability 0 12 24 36 48 60 72 84 96 108 120 Months since registration Numbers of patients at risk MCP 150 132 123 110 98 87 80 55 22 0 CHOP1 383 351 332 307 286 243 161 70 24 0 CHOP2 287 260 208 120 53 3 0 R-CHOP 474 352 230 130 55 5 0 Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

  16. Comparison of two consecutive study generations of the GLSG (cont’d) Overall survival Hiddemann W, et al. Blood 2006;108:147a (Abstract 483) *Adjusted for FLIPI and rituximab

  17. Conclusions • Comparison of the two consecutive GLSG studies 1996 and 2000 reveals for the 2000 trial a significant improvement of • response rate • TTF • OS • This improvement is due to the addition of rituximab Hiddemann W, et al. Blood 2006;108:147a (Abstract 483)

More Related